ZA202203564B - The use of the agent for inducing specific immunity against severe acute respiratory syndrome virus sars-cov-2 in subjects above 60 years of age and/or having chronic diseases (variants) - Google Patents

The use of the agent for inducing specific immunity against severe acute respiratory syndrome virus sars-cov-2 in subjects above 60 years of age and/or having chronic diseases (variants)

Info

Publication number
ZA202203564B
ZA202203564B ZA2022/03564A ZA202203564A ZA202203564B ZA 202203564 B ZA202203564 B ZA 202203564B ZA 2022/03564 A ZA2022/03564 A ZA 2022/03564A ZA 202203564 A ZA202203564 A ZA 202203564A ZA 202203564 B ZA202203564 B ZA 202203564B
Authority
ZA
South Africa
Prior art keywords
seq
agent
genome
cov
age
Prior art date
Application number
ZA2022/03564A
Inventor
Vadimovna Zubkova Olga
Andreevna Ozharovskaia Tatiana
Vadimovna Dolzhikova Inna
Popova Olga
Viktorovich Shchebliakov Dmitrii
Mikhailovna Grousova Daria
Shahmirovna Dzharullaeva Alina
Ildarovich Tukhvatulin Amir
Mikhailovna Tukhvatulina Natalia
Nikolaevich Shcherbinin Dmitrii
Bulatovich Esmagambetov Ilias
Alexandrovna Tokarskaya Elizaveta
Sergeevna Erokhova Alina
Magometovna Izhaeva Fatima
Leonidovna Lubenets Nadezhda
Sergeevich Semikhin Aleksandr
Savelievich Naroditsky Boris
Yuryevich Logunov Denis
Leonidovich Gintsburg Aleksandr
Aleksandrovich Chernetsov Vladimir
Vladimirovich Kriukov Evgenii
Fedorovich Babira Vladimir
Anatolievich Kutaev Dmitrii
Yakovlevna Loginova Svetlana
Anatolevna Nikitenko Natalia
Andrei Gennadevich Botikov
Original Assignee
Federal State Budgetary Institution National Res Centre For Epidemiology And Microbiology Named Afte
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2021104430A external-priority patent/RU2744442C1/en
Application filed by Federal State Budgetary Institution National Res Centre For Epidemiology And Microbiology Named Afte filed Critical Federal State Budgetary Institution National Res Centre For Epidemiology And Microbiology Named Afte
Publication of ZA202203564B publication Critical patent/ZA202203564B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention relates to the field of biotechnology, immunology and virology. The use of the agent is disclosed, said agent containing a component 1, which is an agent in the form of expression vector based on genome of recombinant strain of human adenovirus serotype 26 with E1 and E3 sites deleted from the genome, and the site ORF6-Ad26 is substituted for ORF6-Ad5 with integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, and/or containing a component 2, which is an agent in the form of expression vector based on genome of recombinant strain of human adenovirus serotype 5 with E1 and E3 sites deleted from the genome with integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2 in subjects above 60 years of age and/or having chronic diseases. In addition the use of the agent is disclosed, said agent containing a component 1, which is an agent in the form of expression vector based on genome of recombinant strain of human adenovirus serotype 26 with E1 and E3 sites deleted from the genome, and the site ORF6-Ad26 is substituted for ORF6-Ad5 with integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, and also containing a component 2, which is an agent in the form of expression vector based on genome of recombinant strain of simian adenovirus serotype 25 with E1 and E3 sites deleted from the genome with integrated expression cassette selected from SEQ ID NO:4, SEQ ID NO:2, SEQ ID NO:3, or containing only component 2 for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2 in subjects above 60 years of age and/or having chronic diseases. Furthermore, the use of the agent is disclosed, said agent containing a component 1, which is an agent in the form of expression vector based on genome of recombinant strain of simian adenovirus serotype 25 with E1 and E3 sites deleted from the genome with integrated expression cassette selected from SEQ ID NO:4, SEQ ID NO:2, SEQ ID NO:3, and also containing a component 2, which is an agent in the form of expression vector based on genome of recombinant strain of human adenovirus serotype 5 with E1 and E3 sites deleted from the genome with the integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2 in subjects above 60 years of age and/or having chronic diseases. The inventions provide effective induction of the immune response against SARS-CoV-2 virus in subjects above 60 years of age and also having chronic diseases.
ZA2022/03564A 2021-02-21 2022-03-28 The use of the agent for inducing specific immunity against severe acute respiratory syndrome virus sars-cov-2 in subjects above 60 years of age and/or having chronic diseases (variants) ZA202203564B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2021104430A RU2744442C1 (en) 2021-02-21 2021-02-21 Use of agent for induction of specific immunity against severe acute respiratory syndrome sars-cov-2 for population revaccination in people over 60 and/or with chronic diseases (versions)
PCT/RU2022/000045 WO2022177465A1 (en) 2021-02-21 2022-02-18 The use of the agent for inducing immunity to sars-cov-2

Publications (1)

Publication Number Publication Date
ZA202203564B true ZA202203564B (en) 2023-11-29

Family

ID=82850909

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2022/03564A ZA202203564B (en) 2021-02-21 2022-03-28 The use of the agent for inducing specific immunity against severe acute respiratory syndrome virus sars-cov-2 in subjects above 60 years of age and/or having chronic diseases (variants)

Country Status (9)

Country Link
EP (1) EP4294439A1 (en)
JP (1) JP2023507543A (en)
KR (1) KR20230175091A (en)
CN (1) CN115226392A (en)
BR (1) BR112022005920A2 (en)
CA (1) CA3156448A1 (en)
IL (1) IL291803B1 (en)
MX (1) MX2022004060A (en)
ZA (1) ZA202203564B (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2731342C9 (en) * 2020-08-22 2021-10-05 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Pharmaceutical agent and method for use thereof for inducing specific immunity to virus of severe acute respiratory syndrome sars-cov-2 (embodiments)

Also Published As

Publication number Publication date
JP2023507543A (en) 2023-02-24
MX2022004060A (en) 2022-09-19
IL291803B1 (en) 2024-03-01
KR20230175091A (en) 2023-12-29
CA3156448A1 (en) 2022-08-21
CN115226392A (en) 2022-10-21
IL291803A (en) 2022-06-01
EP4294439A1 (en) 2023-12-27
BR112022005920A2 (en) 2023-11-07

Similar Documents

Publication Publication Date Title
AR121931A1 (en) IMMUNOBIOLOGICAL AGENT AND METHOD OF USE THEREOF TO INDUCE SPECIFIC IMMUNITY AGAINST SARS-CoV-2 SEVERE ACUTE RESPIRATORY SYNDROME VIRUS (VARIANTS)
Zhao et al. Airway memory CD4+ T cells mediate protective immunity against emerging respiratory coronaviruses
Jackson et al. Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox
BR0111366A (en) Recombinant Porcine Respiratory and Respiratory Syndrome Virus (prrsv) Vaccine
ZA202202986B (en) Agent for induction of specific immunity against severe acute respiratory syndrome coronavirus (sars-cov-2) in liquid form (versions)
MX2021003199A (en) Vaccines to prevent covid-19 based on non-glycosylated sites of the receptor binding domain (rbd) of the s protein of the sars-cov-2 virus.
US20130058971A1 (en) Innoculation of recombinant viral vectors for rapid pre-exposure prevention and post-exposure protection against alphavirus-induced encephalitides
ZA202203564B (en) The use of the agent for inducing specific immunity against severe acute respiratory syndrome virus sars-cov-2 in subjects above 60 years of age and/or having chronic diseases (variants)
Xie et al. Immune interference in effectiveness of influenza and COVID-19 vaccination
Ahmed et al. Individual and synergistic anti-coronavirus activities of SOCS1/3 antagonist and interferon α1 peptides
BR112017013270A2 (en) "dengue virus vaccine composition, methods for inducing a dengue immune response, reducing the likelihood of dengue infection, or preventing or alleviating dengue symptoms, and use of a dengue virus vaccine composition."
ZA202301438B (en) Aa v5-based vaccine against sars-cov-2
ZA202202322B (en) Expression vector against severe acute respiratory syndrome virus sars-cov-2
ZA202203565B (en) The use of the agent for induction of specific immunity against severe acute respiratory syndrome virus sars-cov-2 for revaccination of population (variants)
MX2022004059A (en) Induction of immunity to sars-cov-2 in children.
AR124744A1 (en) AGENT FOR USE IN INDUCING SPECIFIC IMMUNITY AGAINST SARS-CoV-2 SEVERE ACUTE RESPIRATORY SYNDROME VIRUS IN SUBJECTS OVER 60 YEARS OF AGE AND/OR HAVING CHRONIC DISEASES (VARIANTS)
BR112022004778A2 (en) AGENT FOR SPECIFIC IMMUNITY INDUCTION AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARSCOV-2 IN LYOPHILIZED FORM (VARIANTS) AND USE
ZA202202321B (en) Pharmaceutical agent for inducing specific immunity against sars-cov-2
UY39582A (en) VACCINE BASED ON AAV5 FOR THE INDUCTION OF SPECIFIC IMMUNITY AGAINST SARSCOV-2 AND/OR THE PREVENTION OF SARSCOV-2 RELATED CORONAVIRUS INFECTION
ATE310807T1 (en) SEPARATION OF A HUMAN RETROVIRUS
AR124745A1 (en) AGENT FOR USE IN THE INDUCTION OF SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-CoV-2 FOR POPULATION REVACCINATION (VARIANTS)
Sharma et al. Virus which is More Deadly than World War Three-Coronaviruses (CoVs)
Abouelhassan Pathogenicity, Therapeutic Candidates and Vaccines of Novel Coronavirus Disease (COVID-19): A Literature
EP4282429A1 (en) Multivalent covid-19 vaccines based on adenoviral vectors
RU2021104140A (en) A NEW WEAKENED VIRUS STRAIN AND ITS USE AS A VACCINE